Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

A new strategic initiative spearheaded by the Danish Embassy in Malaysia has brought together major Danish companies to ...

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 700 from DKK 900 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...